Literature DB >> 12948039

Gastroduodenal Helicobacter pylori infection diagnosed by Helicobacter pylori stool antigen is related to atherosclerosis.

Ali K Adiloglu1, Cem Nazli, Buket Cicioglu-Aridogan, Ozan Kinay, Rabia Can, Oktay Ergene.   

Abstract

OBJECTIVE: The causative relation between Helicobacter pylori (H. pylori) and atherosclerosis has been determined as seropositivity or determination of H. pylori from atherome plaques by molecular methods. The site of entrance and the reservoir of the bacteria in the body is still a subject of discussion. In this study Helicobacter pylori stool antigen (HpSA) which shows gastrointestinal system colonization and infection with high specificity and sensitivity was determined in atherosclerotic, ectatic and angiographically normal groups. METHODS AND
RESULTS: A total of 62 patients was categorized according to diagnostic coronary angiography as 12 had normal coronary arteries, eight had one, 18 had two, and 12 had three atherosclerotic coronary arteries. Twelve patients had ectatic vessels. There were 27 (44%) HpSA positive and 35 (56%) HpSA negative patients. There was a statistically significant relation between HpSA positivity and the degree of vessel involvement in coronary artery disease (CAD) patients, essentially between the group with three vessels (83%) obstructed and the normal group (25%). Ectatic vessel group had a higher incidence (50%) of HpSA positivity compared to the control group but not enough for statistical significance.
CONCLUSIONS: The results indicate that gastrointestinal system H. pylori colonization increases the risk of atherosclerosis. We may speculate that the reservoir and spread of H. pylori is via gastrointestinal tract. Studies may be performed to detect whether gastrointestinal tract H. pylori infection treatment will decrease the risk of coronary artery damage caused by H. pylori.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12948039     DOI: 10.2143/AC.58.4.2005291

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  8 in total

1.  Ectasia and severe atherosclerosis: relationships with chlamydia pneumoniae, helicobacterpylori, and inflammatory markers.

Authors:  Ali K Adiloglu; Rabia Can; Cem Nazli; Ahmet Ocal; Oktay Ergene; Gulgun Tinaz; Nesimi Kisioglu
Journal:  Tex Heart Inst J       Date:  2005

2.  Association between Helicobacter pylori infection and angiographically demonstrated coronary artery disease: A meta-analysis.

Authors:  Xin-Juan Yu; Xuan Yang; Lei Feng; Li-Li Wang; Quan-Jiang Dong
Journal:  Exp Ther Med       Date:  2017-01-05       Impact factor: 2.447

3.  Helicobacter pylori seropositivity and stool antigen in patients with hyperemesis gravidarum.

Authors:  R Sinan Karadeniz; Ozlem Ozdegirmenci; M Metin Altay; Ayse Solaroglu; Serdar Dilbaz; Nedret Hizel; Ali Haberal
Journal:  Infect Dis Obstet Gynecol       Date:  2006

Review 4.  Helicobacter pylori infection and eye diseases: a systematic review.

Authors:  Sergio Claudio Saccà; Aldo Vagge; Alessandra Pulliero; Alberto Izzotti
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

5.  Association between Helicobacter pylori Infection and Colorectal Adenomatous Polyps.

Authors:  Wen Yang; Xueqing Yang
Journal:  Gastroenterol Res Pract       Date:  2019-12-18       Impact factor: 2.260

6.  An Updated Meta-Analysis of the Relationship Between Helicobacter pylori Infection and the Risk of Coronary Heart Disease.

Authors:  Ling Tong; Bei-Bei Wang; Fei-Hong Li; Shu-Ping Lv; Fei-Fei Pan; Xin-Jiang Dong
Journal:  Front Cardiovasc Med       Date:  2022-04-29

Review 7.  Non-invasive diagnostic tests for Helicobacter pylori infection.

Authors:  Lawrence Mj Best; Yemisi Takwoingi; Sulman Siddique; Abiram Selladurai; Akash Gandhi; Benjamin Low; Mohammad Yaghoobi; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15

8.  Influence of Helicobacter pylori Infection on Metabolic Syndrome in Old Chinese People.

Authors:  Wen Yang; Cunfu Xuan
Journal:  Gastroenterol Res Pract       Date:  2016-06-27       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.